Establishing a Consistent Framework & Endpoints to Optimize Clinical Trial Design
Time: 11:20 am
day: Day One
Details:
- Evaluate whether new therapeutics should be included or be tested side
by side to approved inhibitors - Improve the predictability of endpoints from Phase I to Phase II, and Phase II to Phase III clinical trials
- Map out the most promising surrogate endpoints and biomarkers that
allow for earlier identification of drug efficacy
